Cargando…

Transition from secukinumab to adalimumab in COVID‐19‐induced psoriasis flare‐up treatment: A case report

Coronavirus disease 2019 (COVID‐19) is known to trigger systemic inflammation and elicit immune responses, which may disrupt the delicate balance of cytokines involved in psoriatic regulation. Compared to other therapies in dermatology, biologics used for immune‐mediated dermatological diseases have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yuting, Qiu, Yangyang, Chen, Meiqing, Huang, Ling, Lin, Xinyu, Qiu, Xiaoyan, Wei, Yi, Gao, Lujuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568048/ https://www.ncbi.nlm.nih.gov/pubmed/37841881 http://dx.doi.org/10.1002/ccr3.8047

Ejemplares similares

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis
por: Zhao, Zheng, et al.
Publicado: (2022)

Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
por: Pan, Ran, et al.
Publicado: (2022)

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Fitzgerald, Timothy, et al.
Publicado: (2023)

The Tuberculosis Positive Conversion Rate Among Psoriasis Patients Treated with Adalimumab and Secukinumab: A Single-Center Retrospective Study in China
por: Xiao, Yue, et al.
Publicado: (2022)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Arthropathic psoriasis complicated by a paradoxical reaction in the form of erythrodermic psoriasis following adalimumab and by an allergic reaction following infliximab which was successfully managed with secukinumab
por: Tichy, Martin
Publicado: (2019)

Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
por: Li, Gaojie, et al.
Publicado: (2022)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Nivolumab/tozinameran: Flare-up of psoriasis: case report
Publicado: (2021)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang, Eric J, et al.
Publicado: (2018)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Successful treatment of adalimumab-resistant palmoplantar pustulosis with secukinumab: a case report
por: Li, Qing-Yang, et al.
Publicado: (2020)

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
por: Gisondi, Paolo, et al.
Publicado: (2022)

Generalized Pustular Psoriasis Flare-Up after Both Doses of BBIBP-CorV Vaccination in a Patient under Adalimumab Treatment: A Case Report
por: Dayani, Dorsa, et al.
Publicado: (2023)

Secukinumab for the treatment of generalized pustular psoriasis: A case report
por: Li, Jiayan, et al.
Publicado: (2023)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
por: Li, Ying, et al.
Publicado: (2022)

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison
por: Maksymowych, Walter P., et al.
Publicado: (2018)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Secukinumab for psoriasis in a patient with familial Mediterranean fever
por: Cannavò, Serafinella P., et al.
Publicado: (2019)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
por: Tiberio, Rossana, et al.
Publicado: (2019)

Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
por: Körber, Andreas, et al.
Publicado: (2021)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
por: Narbutt, Joanna, et al.
Publicado: (2023)

Successful Treatment of Recurrent Pustular Psoriasis of Pregnancy with Secukinumab: A Case Report
por: LIU, Na, et al.
Publicado: (2020)

Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study
por: Tamer, Funda, et al.
Publicado: (2020)

The effect of secukinumab treatment for psoriasis on serum cytokines and correlation with disease severity
por: Wu, Lan‐Tu‐Ya, et al.
Publicado: (2023)

Psoriasis Flare-Up in a Patient Treated With Docetaxel for Metastatic Prostate Cancer
por: Kurian, Matthew, et al.
Publicado: (2023)

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab
por: Giuseppe, Pistone, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
por: Johar, Asmah, et al.
Publicado: (2019)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3uuf9lcq1a0e6fuhktl7ku0vf3